-transparent.png){kind=logo}
The effect of magnesium deficiency on vitamin D metabolism was assessed in 23 hypocalcemic magnesium-deficient patients by measuring the serum concentrations of 25-hydroxyvitamin D (25OHD) and 1,25-dihydroxyvitamin D [1,25-(OH)2D] before, during, and after 5-13 days of parenteral magnesium therapy. Magnesium therapy raised mean basal serum magnesium [1.0 +/- 0.1 (mean +/- SEM) mg/dl] and calcium levels (7.2 +/- 0.2 mg/dl) into the normal range (2.2 +/- 0.1 and 9.3 +/- 0.1 mg/dl, respectively; P less than 0.001). The mean serum 25OHD concentration was in the low normal range (13.2 +/- 1.5 ng/ml) before magnesium administration and did not significantly change after this therapy (14.8 +/- 1.5 ng/ml). Sixteen of the 23 patients had low serum 1,25-(OH)2D levels (less than 30 pg/ml). After magnesium therapy, only 5 of the patients had a rise in the serum 1,25-(OH)2D concentration into or above the normal range despite elevated levels of serum immunoreactive PTH. An additional normocalcemic hypomagnesemic patient had low 1,25-(OH)2D levels which did not rise after 5 days of magnesium therapy. The serum vitamin D-binding protein concentration, assessed in 11 patients, was low (273 +/- 86 micrograms/ml) before magnesium therapy, but normalized (346 +/- 86 micrograms/ml) after magnesium repletion. No correlation with serum 1,25-(OH)2D levels was found. The functional capacity of vitamin D-binding protein to bind hormone, assessed by the internalization of [3H]1,25-(OH)2D3 by intestinal epithelial cells in the presence of serum was not significantly different from normal (11.42 +/- 1.45 vs. 10.27 +/- 1.27 fmol/2 X 10(6) cells, respectively). These data show that serum 1,25-(OH)2D concentrations are frequently low in patients with magnesium deficiency and may remain low even after 5-13 days of parenteral magnesium administration. The data also suggest that a normal 1,25-(OH)2D level is not required for the PTH-mediated calcemic response to magnesium administration. We conclude that magnesium depletion may impair vitamin D metabolism.
R K Rude, and
J S Adams, and
E Ryzen, and
D B Endres, and
H Niimi, and
R L Horst, and
J G Haddad, and
F R Singer
June 2012,
Clinical biochemistry,
R K Rude, and
J S Adams, and
E Ryzen, and
D B Endres, and
H Niimi, and
R L Horst, and
J G Haddad, and
F R Singer
June 1990,
Clinical rheumatology,
R K Rude, and
J S Adams, and
E Ryzen, and
D B Endres, and
H Niimi, and
R L Horst, and
J G Haddad, and
F R Singer
August 1981,
The Journal of pediatrics,
R K Rude, and
J S Adams, and
E Ryzen, and
D B Endres, and
H Niimi, and
R L Horst, and
J G Haddad, and
F R Singer
May 1987,
Archives of disease in childhood,
R K Rude, and
J S Adams, and
E Ryzen, and
D B Endres, and
H Niimi, and
R L Horst, and
J G Haddad, and
F R Singer
May 1985,
Calcified tissue international,
R K Rude, and
J S Adams, and
E Ryzen, and
D B Endres, and
H Niimi, and
R L Horst, and
J G Haddad, and
F R Singer
January 2012,
Anticancer research,
R K Rude, and
J S Adams, and
E Ryzen, and
D B Endres, and
H Niimi, and
R L Horst, and
J G Haddad, and
F R Singer
June 1986,
The Journal of clinical endocrinology and metabolism,
R K Rude, and
J S Adams, and
E Ryzen, and
D B Endres, and
H Niimi, and
R L Horst, and
J G Haddad, and
F R Singer
September 1988,
The New England journal of medicine,
R K Rude, and
J S Adams, and
E Ryzen, and
D B Endres, and
H Niimi, and
R L Horst, and
J G Haddad, and
F R Singer
March 1993,
The Journal of pediatrics,
R K Rude, and
J S Adams, and
E Ryzen, and
D B Endres, and
H Niimi, and
R L Horst, and
J G Haddad, and
F R Singer
January 2013,
PloS one,
